Amicus Therapeutics to Announce First Quarter 2013 Financial Results on May 9, 2013

Amicus Therapeutics to Announce First Quarter 2013 Financial Results on May 9,
2013

CRANBURY, N.J., May 2, 2013 (GLOBE NEWSWIRE) -- Amicus Therapeutics
(Nasdaq:FOLD) today announced a conference call and live audio webcast on
Thursday, May 9, 2013 at 5:00 p.m. ET to discuss financial results for the
first quarter ended March 31, 2013.

The call with be hosted by John F. Crowley, Chairman and Chief Executive
Officer. He will be joined on the call by additional members of the Amicus
management team. Interested participants and investors may access the
conference call at 5:00 p.m. ET by dialing 877-303-5859 (U.S./Canada) or
678-224-7784 (international).

A live audio webcast can also be accessed via the Investors section of the
Amicus Therapeutics corporate web site at
http://ir.amicustherapeutics.com/events.cfm, and will be archived for 30 days.
Web participants are encouraged to go to the web site 15 minutes prior to the
start of the call to register, download and install any necessary software.
The slide presentation for the conference call/webcast will also be available
at http://ir.amicustherapeutics.com/events.cfm.

A telephonic replay of the call will be available for seven days beginning at
8:00 p.m. ET on May 9, 2013. Access numbers for this replay are 855-859-2056
(U.S./Canada) and 404-537-3406 (international); participant code 64638686.

About Amicus Therapeutics

Amicus Therapeutics (Nasdaq:FOLD) is a biopharmaceutical company at the
forefront of therapies for rare and orphan diseases. The Company is developing
novel, first-in-class treatments for a broad range of human genetic diseases,
with a focus on delivering new benefits to individuals with lysosomal storage
diseases. Amicus' lead programs include the small molecule pharmacological
chaperones migalastat HCl as a monotherapy and in combination with enzyme
replacement therapy (ERT) for Fabry disease; and AT2220 (duvoglustat HCl) in
combination with ERT for Pompe disease.

FOLD-G

CONTACT: Amicus Therapeutics
         Sara Pellegrino
         (609) 662-5044
         spellegrino@amicusrx.com